Register or Sign in to Save this opportunity, or Send an Inquiry.
Anti-abdominal Obesity Drug, Anti-retinopathy Drug, Anti-periodontitis Drug, Etc.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
The Company is developing an anti-abdominal obesity botanical drug, ALS-L1023, which is in phase III clinical trial in Korea. The company has already commercialized anti-abdominal obesity dietary supplement (Ob-X).
Send an Inquiry

- AngioLab possess patent protected core technology and extensive know how and experience in angiogenesis research. The development of anti-angiogenic multi-functional drugs and nutraceuticals are targeting a variety of angiogenesis-dependent diseases including cancer, arthritis, ocular disease, psoriasis, and obesity.

- The Company has focused on screening anti-angiogenic and Matrix Metalloproteinases (MMP) inhibitory substances from various sources and has valuable candidates in forms of botanical drugs, synthetic compounds, and recombinant proteins.

- For the past eleven years, the Company has been awarded numerous government research grants for the developing of its products and technologies.

More than 60 international and domestic patents related to angiogenesis inhibitors have been filed with many of those already issued. Among its candidates, a plant based product showed potent anti-angiogenic activity through oral route without having any noticeable side effects, which demonstrated that it can be administered to patients for a long period of time as angiogenesis inhibitors.

- The Company leverages its drug development activities through strong collaborations with academic institutions and hospitals. The company is trying to commercialize its anti- angiogenic candidates as anti-abdominal obesity drug (ALS-L1023), anti-retinopathy drug (McEye), anti-periodontitis drug (Periostatin), and anti-wrinkle cosmetics (Wrinklestat).

- Anti-abdominal obesity drug (ALS-L1023) is in phase III clinical trial in Korea, and IND filing to US FDA is in preparation for phase II clinical trial in USA.

Anti-abdominal obesity dietary supplement (Ob-X), of which efficacy has been proven in three human studies, got KFDA approval of specific health functional food with health claim.

- Obesity has emerged as a major public health problem due to its high prevalence and association with increased risk for development of metabolic syndrome such as type 2 diabetes mellitus and cardiovascular diseases. Visceral fat has been recognized as a contributor to the pathogenesis of the obesity-related metabolic syndrome.

- There are many anti-obesity drugs and dietary supplements in the market, and most of them are focusing on weight loss with mechanism of suppressing appetite to reduce food intake or inhibiting lipase or increasing metabolic activity. However, none of those products in the market appears to be used on a long-term basis due to adverse side effects.

- Adipose tissue is highly vascularized and each adipocyte is nourished by an extensive capillary network. Similar to tumor tissue, adipose tissue can exceptionally grow and regress throughout adulthood. Substantial scientific evidences demonstrate the growth of both tumor tissue and adipose tissue depending on angiogenesis.

- A research team at Harvard University found that treatment of angiogenesis inhibitors in obese mice resulted in weight reduction and adipose tissue loss, showing that adipose tissue mass can be regulated by its vasculature. Angiogenesis inhibitors change the vascularity of adipose tissue and result in adipose tissue regression. The results from the study introduce novel approach for prevention and treatment of obesity.

- Unlike other anti-obesity products, which decrease both lean and fat mass, the weight loss induced by angiogenesis inhibitors specifically came from loss of adipose tissue mass. Because angiogenesis rarely occur in normal physiological conditions and angiogenesis inhibitors target only newly formed vessels, angiogenesis inhibitors have a high specificity for reducing adipose tissue with little toxicity.

1) ALS-L1023 : Anti-abdominal obesity drug

- ALS-L1023 inhibits angiogenesis targeting VEGF and MMP inhibition

- ALS-L1023 is botanical drug prepared by activity-guided fractionation from one herb

- It is standardized by two reference compounds

- Preclinical studies were completed in Australia and Korea

- Visceral fat was reduced in phase II human trial by CT analysis

- Phase III human clinical trial is in progress

Title of Phase III study : A multi-center, 12-week randomized, double-blind, placebo-controlled phase III clinical trial to assess the effect of ALS-L1023 1200mg on visceral fat change in abdominally obese patients with metabolic syndrome

- Pre-IND meeting request to US FDA for phase II human trial preparation in USA

- 8 patents registered and 17 patents pending

2) McEye : Anti-retinopathy drug

- Application of ALS-L1023 to angiogenesis-dependent ocular diseases such as Age-related Macular Degeneration(AMD) and Diabetic retinopathy(DR)

- Efficacy was tested in ROP (Retinopathy of Prematurity) model

- Toxicological studies were completed

- 6 patents registered and 9 patents pending

3) Periostatin : Anti-periodontitis drug

- Botanical drug

- Inhibition of MMP-1, -8, -13 to protect periodontal ligaments and alveolar bone (tooth loss)

- The MMP inhibitory effect is similar to that of Doxycycline, a commercial MMP inhibitor FDA approved for periodontal disease

- Completed efficacy study with beagle dogs

- 1 patent registered and 5 patents pending

4) Wrinklestat : Anti- wrinkle cosmetics

- Single compound

- Prevention of UV-induced wrinkle formation by inhibiting MMPs

- Single dose acute toxicity, primary skin irritation, eye irritation, skin sensitization, photo-toxicity, photo-sensitization and anti-wrinkle tests were completed

- Efficacy and safety studies in human were completed

- Listed in ICID (Wrinklestat as a trade-name and Methoxychalcone as INCI name)

- 2 patents registered and 2 patents pending

5) Ob-X : Anti-abdominal obesity dietary supplement

- Inhibition of angiogenesis and matrix metalloproteinase targeting adipose tissue

- Three human studies completed

- Reduction of visceral fat

- KFDA approval of specific functional food with health claim

- Export Ob-X raw material to EU, US and Japan

- 6 patents registered and 9 patents pending

Last Updated Jan 2018
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833